RAG1 and neoplasm: To assess whether KRASG12Cinhibition could stimulate anti-tumour immunity in vivo wetested the response of KPARG12C subcutaneous tumours to AZ-8037 inboth immune-competent and Rag1-/- mice.Vehicle-treated KPARG12C tumours grew slower in immune-competent micecompared to Rag1-/- mice, similarly to what weobserved with the parental KPAR tumours (Fig.6A).